A Safety/Proof-of-Concept Study to Evaluate the Effects of Oral QLT091001 in Children With Leber Congenital Amaurosis (LCA)
An open-label, Phase Ib safety/proof-of-concept study to evaluate the effects of oral QLT091001 in children with Leber Congenital Amaurosis (LCA) due to inherited deficiencies of retinal pigment epithelial 65 protein (RPE65) or lecithin-retinol acyltransferase (LRAT).
The purpose of this study is to determine if 7 days of treatment with oral QLT091001 is safe and can improve visual function in children with LCA.
For more information, visit ClinicalTrials.gov.
Contact Information
QLT Medical Information
1-800-663-5486
medaffairs@qltinc.com
|
